What is the recommended antiviral treatment for influenza in otherwise healthy adults, high‑risk patients, and hospitalized patients?

Influenza Antiviral Treatment Recommendations

Start antiviral treatment immediately with a neuraminidase inhibitor (oseltamivir, zanamivir, or peramivir) for all hospitalized patients, high-risk outpatients, and those with severe/progressive illness, regardless of illness duration or vaccination status. 1

Treatment Algorithm by Patient Category

Hospitalized Patients (Any Age)

• Initiate treatment immediately with a single neuraminidase inhibitor (NAI), regardless of how long symptoms have been present 1
• First-line options:
  • Oral oseltamivir (preferred for most patients)
  • Inhaled zanamivir
  • IV peramivir (single dose option)
• Standard duration: 5 days for uncomplicated cases 1
• Consider extending treatment beyond 5 days for severe lower respiratory disease (pneumonia, ARDS) or immunocompromised patients, as viral replication is often prolonged 1
• Do NOT use higher than FDA-approved doses 1
• Do NOT combine multiple NAIs 1

High-Risk Outpatients

Treat immediately if patient has ANY of these risk factors:

• Chronic medical conditions (cardiac, pulmonary, renal, hepatic, metabolic disorders)
• Immunocompromised state
• Age <2 years or ≥65 years
• Pregnancy or within 2 weeks postpartum 1

Treatment regimen:

• 5-day course of oral oseltamivir, inhaled zanamivir, or single-dose IV peramivir 1
• Start as soon as possible, ideally within 48 hours of symptom onset for maximal benefit
• However, do NOT withhold treatment if presenting beyond 48 hours - observational data suggests benefit even with late initiation in high-risk patients 2

Otherwise Healthy Outpatients

• May consider treatment if it can be started within 48 hours of symptom onset 1
• Benefits are modest: approximately 1 day reduction in illness duration 3
• The clinical benefit must be weighed against side effects (particularly gastrointestinal with oseltamivir) 3, 4
• This is optional, not mandatory 1

Severe or Progressive Illness (Any Age, Outpatient)

• Treat immediately, regardless of illness duration 1
• Same regimens as hospitalized patients

Critical Management Considerations

Bacterial Coinfection

Empirically add antibiotics in addition to antivirals for:

• Patients presenting with severe disease initially (extensive pneumonia, respiratory failure, hypotension, persistent fever) 1
• Patients who deteriorate after initial improvement 1
• Consider bacterial workup if no improvement after 3-5 days of antiviral treatment 1

Treatment Failure

If patients fail to improve or deteriorate despite antiviral therapy:

• Investigate other causes beyond influenza 1
• Consider NAI resistance testing for:
  • Immunocompromised patients with persistent viral replication (>7-10 days) 1
  • Patients who developed influenza while on NAI prophylaxis 1
  • Severe influenza not improving with evidence of ongoing viral replication 1

What NOT to Do

Strong recommendations AGAINST:

• Corticosteroids for seasonal influenza treatment (associated with increased mortality and bacterial superinfection) 1, 2
• Antibiotics in non-severe influenza without evidence of bacterial infection 5
• Combination NAI therapy 1
• Higher than standard NAI doses 1

Common Pitfalls to Avoid

1. Do not delay treatment waiting for test results in hospitalized or high-risk patients with suspected influenza - start empirically 1

2. Do not withhold treatment beyond 48 hours in hospitalized, severely ill, or high-risk patients - observational data supports benefit even with late initiation 2

3. Do not use rapid antigen tests alone in hospitalized patients - they have poor sensitivity; use RT-PCR or other molecular assays 1

4. Do not forget to assess for bacterial coinfection in severe presentations - this is a major cause of mortality 1

5. Do not administer inhaled zanamivir to intubated patients using the commercial dry powder formulation via nebulization - it causes ventilator malfunction 2

Drug Selection Nuances

• Oseltamivir is most widely studied and preferred for most situations, including severe illness 1, 4
• Zanamivir (inhaled) is more effective against influenza B and works against most oseltamivir-resistant strains, but avoid in patients with underlying airway disease 2, 4
• IV zanamivir should be obtained for intubated patients with concerns about gastric absorption 2
• Baloxavir shows promise with superior viral load reduction but is not yet included in the primary IDSA guidelines; WHO conditionally recommends it for high-risk non-severe cases and severe cases 5, 6